Week In Review: Beijing BoomRay Closes $43 Million A Round For Novel Radionuclide Drugs
Beijing BoomRay Pharma has completed a $43 million Series A funding to develop novel radionuclide drugs that integrate diagnosis and treatment. Read more here...
Source: seekingalpha.com